Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleUk· February 5, 2026

Bank of England holds interest rates at 3.75%

View original at uk.finance.yahoo.com
Bank of England holds interest rates at 3.75% The Bank of England has left interest rates on hold at 3.75% as expected, but relief may be coming for UK borrowers within months…
Opening lines of the source · Uk · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Monetary Policy Committee will continue to face a delicate balancing act between supporting growth and preventing inflation from becoming entrenched, with the next rate cut expected in April

    80% confidence
  • The bank will have to act soon if it intends to cut, before the disinflationary window closes in the second half of the year

    80% confidence
  • The Bank of England is balancing signs of improving growth against stubborn inflation and has pushed pause on interest rate cuts

    80% confidence
  • As long as inflation remains above 3%, there will be concern among rate setters that price pressures could become more persistent

    80% confidence
  • Headline inflation will drop to 1.8% in April from 3.4% in December, taking it below the bank's 2% target

    80% confidence
  • A rate cut in March remains firmly in the picture, with weakness in the labour market, falling energy and transport costs and cheaper Chinese goods potentially swaying more policymakers

    80% confidence
  • Risks to inflation from weaker demand and a loosening labour market remain, and the risk of persistent inflation has become less pronounced

    80% confidence
  • April is the most likely time for the next rate cut, when the MPC will have a clearer view of 2026 pay awards and evidence of slack in the economy

    80% confidence
  • The combination of lower inflation ahead and continued softening of the UK labour market should reinforce the central bank's view that the path for monetary policy is towards a lower Bank rate, potentially as early as next month

    80% confidence
  • Inflation expected to decline to about 3% in January, February and March, then reaching level close to 2% target in April and staying there

    80% confidence
  • On the basis of the current evidence, Bank Rate is likely to be reduced further, though decisions on additional easing would become a closer call

    80% confidence
  • Inflation will fall sharply this spring, opening the door to two rate cuts by the summer

    80% confidence
  • The market remains positive following recent drops in the BoE base rate, with hope for further reduction in April

    80% confidence
  • Major central banks are pursuing increasingly divergent policy paths, with pressure for rate cuts in the US, a more patient stance in the eurozone and tighter policy in Australia

    80% confidence
  • Inflation will fall back to around 2% by the spring

    80% confidence
  • Neither the US Federal Reserve nor Bank of England are quite done cutting rates this year, but we may have to wait a while

    80% confidence
  • Expects rate cuts in March and June, a faster pace of easing than markets currently anticipate

    80% confidence
  • Comments from Andrew Bailey suggest the Bank rate is close to its neutral level, meaning markets should not expect many reductions this year

    80% confidence
  • Today's rate decision was expected, but the close vote suggests cuts are not a matter of if, but when

    80% confidence
  • There should be scope for some further reduction in Bank Rate this year, all going well

    80% confidence
  • With the base rate staying at 3.75%, most existing mortgage holders won't see an immediate change, with those on fixed rates completely insulated and tracker/variable rate customers seeing stability

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com